RT期刊文章SR电子T1指南 - 符合治疗及与医疗保健相关的肺炎JF欧洲呼吸道杂志JO EUR RESSIR J FD欧洲呼吸学会SP 878 OP 887 DO 10.1183/09031936.00141110 VO 38 IS 4 A A1 Attridge，R.T.。188bet官网地址A1 Frei，C.R。A1 Restrepo，M.I。A1 Lawson，K.A。A1 Ryan，L.A1 Pugh，M.J.V。A1 Anzueto，A.A1 Mortensen，E.M. YR 2011 UL //www.qdcxjkg.com/content/38/4/4/878.abstract ab Healthcare-shealthcare-cassecation-cassiated肺炎（HCAP）指南，但尚未在2005年提出经过验证。这项研究的目的是比较接受指南符合（GC）HCAP治疗或GC社区获得性肺炎（CAP）治疗的HCAP患者的30天死亡率。我们对美国退伍军人卫生管理局进行了一项基于人群的队列研究。如果患者患有一个或多个HCAP危险因素，并在入院后48小时内接受了抗生素治疗，则应使用。重病患者被排除在外。 Independent risk factors for 30-day mortality were determined in a generalised linear mixed-effect model, with admitting hospital as a random effect. Propensity scores for the probability of receiving GC-HCAP therapy were calculated and incorporated into a second logistic regression model. A total of 15,071 patients met study criteria and received GC-HCAP therapy (8.0%), GC-CAP therapy (75.7%) or non-GC therapy (16.3%). The strongest predictors of 30-day mortality were recent hospital admission (OR 2.49, 95% CI 2.12–2.94) and GC-HCAP therapy (OR 2.18, 95% CI 1.86–2.55). GC-HCAP therapy remained an independent risk factor for 30-day mortality (OR 2.12, 95% CI 1.82–2.48) in the propensity score analysis. In nonsevere HCAP patients, GC-HCAP therapy is not associated with improved survival compared with GC-CAP therapy.